Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last kr164.00 SEK
Change Today -1.00 / -0.61%
Volume 9.8K
VITR On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
Frankfurt
As of 11:29 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

vitrolife ab (VITR) Snapshot

Open
kr163.50
Previous Close
kr165.00
Day High
kr166.50
Day Low
kr162.50
52 Week High
07/14/15 - kr194.00
52 Week Low
10/16/14 - kr114.75
Market Cap
3.6B
Average Volume 10 Days
33.3K
EPS TTM
kr6.56
Shares Outstanding
21.7M
EX-Date
05/6/15
P/E TM
25.0x
Dividend
kr1.50
Dividend Yield
0.91%
Current Stock Chart for VITROLIFE AB (VITR)

Related News

No related news articles were found.

vitrolife ab (VITR) Related Businessweek News

No Related Businessweek News Found

vitrolife ab (VITR) Details

Vitrolife AB (publ), a medical device company, develops, produces, and markets products and systems for assisted reproduction worldwide. It offers fertility products, including follicle aspiration needles, paraffin oil under the OVOIL brand, additional media for in vitro fertilization (IVF) procedures, labware products, vitrification products, and Primo Vision time-lapse embryo monitoring systems. The company’s fertility products also include G-series media, micromanipulation solutions, sperm processing solutions, micropipettes, and slow freezing products. It also provides cell therapy services to researchers and cell therapy companies. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1981 and is headquartered in Goteborg, Sweden.

337 Employees
Last Reported Date: 07/14/15
Founded in 1981

vitrolife ab (VITR) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr4.0M
Compensation as of Fiscal Year 2014.

vitrolife ab (VITR) Key Developments

Vitrolife AB (Publ) Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Vitrolife AB (publ) reported earnings results for the second quarter and six months ended June 30, 2015. For the quarter, the company reported net sales of €184 million against €129 million a year ago. EBIT was €50.5 million against €33.6 million a year ago. Profit before tax was €48.2 million against €31.6 million a year ago. Profit for the period was €38.6 million against €23.1 million a year ago. For the six months, the company reported net sales of €347 million against €249 million a year ago. EBIT was €90.0 million against €63.5 million a year ago. Profit before tax was €90.7 million against €61.2 million a year ago. Profit for the period was €73.8 million against €45.5 million a year ago. Cash flow generated operating activities €40 million against €53 million a year ago.

Vitrolife AB (Publ) Reports Consolidated and Parent Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Vitrolife AB (publ) reported consolidated and parent earnings results for the second quarter and six months ended June 30, 2015. For the six months, on consolidated basis, net sales were SEK 346.540 million against SEK 248.508 million last year. Operating income was SEK 89.958 million against SEK 63.523 million last year. Income after financial items was SEK 90.713 million against SEK 61.194 million last year. Net income attributable to parent company's shareholders was SEK 73.341 million against SEK 45.189 million last year. Earnings per share were SEK 3.38 against SEK 2.28 last year. Return on equity was 21.5% against 24.2% last year. Cash flow from operating activities per share was SEK 1.82 against SEK 2.66 last year. Cash flow from operating activities was SEK 39.606 million against SEK 52.829 million last year. Operating income before depreciation and amortization (EBITDA) was SEK 116 million against SEK 74 million last year. For the second quarter, on consolidated basis, net sales were SEK 184.145 million against SEK 129.436 million last year. Operating income was SEK 50.505 million against SEK 33.604 million last year. Income after financial items was SEK 48.179 million against SEK 31.614 million last year. Net income attributable to parent company's shareholders was SEK 38.354 million against SEK 23.011 million last year. Earnings per share were SEK 5.46 against SEK 1.16 last year. Return on equity was 21.5% against 24.2% last year. Cash flow from operating activities per share was SEK 1.44 against SEK 1.43 last year. Cash flow from operating activities was SEK 31.180 million against SEK 28.436 million last year. Operating income before depreciation and amortization (EBITDA) was SEK 62 million against SEK 38 million last year. For the six months, on parent basis, operating loss was SEK 3.793 million against SEK 1.838 million last year. Income after financial items was SEK 182.663 million against loss after financial items of SEK 2.913 million last year. Net income was SEK 183.134 million against SEK 2.272 million last year. For the second quarter, on parent basis, operating loss was SEK 1.594 million against SEK 2.025 million last year. Income after financial items was SEK 183.806 million against loss after financial items of SEK 2.786 million last year. Net income was SEK 184.026 million against SEK 2.173 million last year.

Vitrolife AB (publ) Reports Unaudited Consolidated and Parent Financial Results for the First Quarter Ended Mar. 31, 2015; Proposes Dividend for Fiscal 2014

Vitrolife AB (publ) reported unaudited consolidated and parent financial results for the first quarter ended Mar. 31, 2015. For the quarter, the group's net sales were SEK 162,396,000 against SEK 119,072,000 for the same period of last year. Operating income was SEK 39,453,000 against SEK 29,920,000 for the same period of last year. Income after financial items was SEK 42,534,000 against SEK 29,580,000 for the same period of last year. Net income attributable to parent company's shareholders was SEK 34,987,000 against SEK 22,178,000 for the same period of last year. Earnings per share was SEK 1.61 against SEK 1.12 for the same period of last year. ROE was 22.5% against 21.3% for the same period of last year. Cash flow from operating activities was SEK 8,426,000 against SEK 24,395,000 for the same period of last year. Profit before tax was SEK 42.5 million against SEK 29.6 million for the same period of last year. For the quarter, the parent company reported operating loss of SEK 2,199,000 against income of SEK 187,000 for the same period of last year. Income after financial items was SEK 1,143,000 against SEK 127,000 for the same period of last year. Net loss was SEK 892,000 against SEK 99,000 for the same period of last year. The company announced that in accordance with the dividend policy of the company, a dividend, or another equivalent form of distribution, shall be proposed annually which on average over time corresponds to 30% of net profits for the year after tax has been paid. The Board has accordingly proposed that the Annual General Meeting adopt a dividend of SEK 1.50 per share for 2014 against 1.00 per share for the last year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VITR:SS kr164.00 SEK -1.00

VITR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bionet Corp 22.80 TWD +1.20
Cryo-Cell International Inc $3.38 USD -0.005
CryoLife Inc $9.90 USD +0.26
Esperite NV €2.56 EUR -0.053
Osiris Therapeutics Inc $18.73 USD +0.59
View Industry Companies
 

Industry Analysis

VITR

Industry Average

Valuation VITR Industry Range
Price/Earnings 24.5x
Price/Sales 5.7x
Price/Book 4.7x
Price/Cash Flow 25.4x
TEV/Sales 5.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VITROLIFE AB, please visit www.vitrolife.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.